The first radioactive drug has been approved for adults with rare cancers known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lutetium-177 (177Lu)–Dotatate is indicated for patients whose tumors are somatostatin receptor-positive.
About 1 in every 27 000 people is diagnosed with a GEP-NET annually. The tumors can occur in the pancreas, stomach, intestines, colon, or rectum. Treatment options are limited after initial therapy fails to stop tumor growth, said Richard Pazdur, MD, director of the FDA’s Center for Drug Evaluation and Research.
Voelker R. First Radioactive Drug for Adults With Rare Cancer. JAMA. 2018;319(9):857. doi:10.1001/jama.2018.1249
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: